Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-PRISM: Ixazomib Combination in Smoldering Multiple Myeloma
NCT02916771Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2016
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in smoldering multiple myeloma (SMM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Proportion Of High Risk SMM Patients Who Are Progression Free at 2 years. Started Oct 2016; status: completed.
02
Drugs
ixazomib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02916771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916771.